Drug-induced pulmonary hypertension in newborns: A review

Current Vascular Pharmacology

Volumn 5, Issue 2, 2007, Pages 129-133

  Silvani, Paolo ^a   Camporesi, Anna ^a  

^a V BUZZI CHILDREN S HOSPITAL   (Italy)

Author keywords

Diazoxide; Newborn; Non steroidal antiinflammatory agents; Octreotide; Persistent pulmonary hypertension of the newborn; Pulmonary hypertension; Serotonin reuptake inhibitors

Indexed keywords

DIAZOXIDE; ENDOTHELIN 1; FLUOXETINE; IBUPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PROSTAGLANDIN; SEROTONIN UPTAKE INHIBITOR; VASODILATOR AGENT;

ABDOMINAL CRAMP; CHOLELITHIASIS; DEPRESSION; DRUG CONTRAINDICATION; DRUG USE; DRUG WITHDRAWAL; ENTEROCUTANEOUS FISTULA; FETUS CIRCULATION; FLUID RETENTION; GESTATIONAL AGE; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LUNG CIRCULATION; LUNG VASCULAR RESISTANCE; NEWBORN DISEASE; PATENT DUCTUS ARTERIOSUS; PERINATAL DRUG EXPOSURE; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PREMATURITY; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; REVIEW; RISK FACTOR; SIDE EFFECT; TACHYCARDIA; THIRD TRIMESTER PREGNANCY; WEIGHT GAIN; ANIMAL; BIRTH; CHEMICALLY INDUCED DISORDER; CIRCULATION; NEWBORN; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD CIRCULATION; DIAZOXIDE; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; OCTREOTIDE; PARTURITION; SEROTONIN UPTAKE INHIBITORS; VASODILATOR AGENTS;

EID: 34247897197     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016107780368316     Document Type: Review

References (59)

1. Lakshminrusimha S, Steinhorn RH. Pulmonary vascular biology during neonatal transition. Clin Perinatol 1999; 26: 601-619.
2. Greenough A, Khetriwal B. Pulmonary Hypertension in the newborn. Paed Resp Rev 2005; 6: 111-116.
3. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000; 105:14-20.
4. Dakshinamurti S. Pathophysiologic Mechanisms of Persistent Pulmonary Hypertension of the Newborn. Pediatr Pulmonol 2005; 39: 492-503.
5. Allen K, Haworth SG. Human postnatal pulmonary arterial remodeling. Ultrastructural studies of smooth muscle cell and connective tissue maturation. Lab Invest 1998; 59: 702-709.
6. Lincoln TM, Komalavillas P, Cornwell TL. Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase. Hypertension 1994; 23: 1141-1147.
7. Moncada S, Higgs A. The L-arginine - nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012.
8. Pearson DL, Dawling S, Walsh WF, Haines JL, Christman BW, Bazyc A, et al. Neonatal pulmonary hypertension-urea-cycle intermediates, nitric oxide production, and carbamoyl.phosphate synthetase function. N Engl J Med 2001; 344: 1832-1838.
9. Turley JE, Nelin LD, Kaplowitz MR, Zhang Y, Fike CD. Exhaled No is reduced at an early stage of hypoxia-induced pulmonary hypertension in newborn piglets. Am J Physiol Lung Cell Mol Physiol 2003; 284: 489-500.
10. Kumar P, Kazzi NJ, Shankran S. Plasma immunoreactive endothelin-1 concentration in infants with persistent pulmonary hypertension of the newborn. Am J Perinatol 1996; 13:335-341.
11. Abman SH, Stenmark KR. Changes in lung eicosanoid content during normal and abnormal transition in perinatal lambs. Am J Physiol 1992; 262: 214-222.
12. Dobyns EL, Wescott JY, Kennaugh JM, Ross MN, Stenmark RK. Eicosanoids decrease with successful extracorporeal membrane oxygenation therapy in neonatal pulmonary hypertension. Am J Resp Crit Care Med 1994; 149: 873-880.
13. Kinsella JP, Ivy DD, Abman SH. Pulmonary vasodilatator therapy in congenital diaphragmatic hernia: acute, late, and chronic pulmonary hypertension. Semin Perinatol 2005; 29(2): 123-128
14. Abman SH. New developments in the pathogenesis and treatment of neonatal pulmonary hypertension. Pediatr Pulmonol Suppl 1999; 18: 201-204
15. Reece EA, Moya F, Yazigi R, Holford T, Duncan C, Ehrenkranz RA. Persistent pulmonary hypertension: assessment of perinatal risk factors. Obstet Gynecol 1987; 70: 696-700
16. Bearer C, Emerson RK, O'Riordan MA, Roitman E, Shackleton C. Maternal tobacco smoke exposure and persistent pulmonary hypertension of the newborn. Environ Health Perspect 1997; 105: 202-206
17. Zenker M, Klinge J, Kruger C, Singer H, Scharf J. Severe pulmonary hypertension in a neonate caused by premature closure of the ductus arteriosus following maternal treatment with diclofenac: a case report. J Perinat Med 1998; 26: 231-234.
18. Rein AJ, Nadjari M, Elchalal U, Nir A. Contraction of the fetal ductus arteriosus induced by diclofenac. Fetal Diagn Ther 1999; 14: 24-25.
19. Auer M, Brezinka C, Eller P, Luze K, Schweigmann U, Schwarzler P. Prenatal diagnosis of intrauterine premature closure of the ductus arteriosus following maternal diclofenac application. Ultrasound Obstet Gynecol 2004; 23: 513-516.
20. Talati AJ, Salim MA, Korones SB. Persistent pulmonary hypertension after maternal naproxen ingestion in a term newborn: a case report. Am J Perinatol 2000; 17: 69-71.
21. Simbi KA, Secchieri S, Rinaldo M, Demi M, Zanardo V. In utero ductal closure following near-term maternal self-medication with nimesulide and acetaminophen. J Obstet Gynaecol 2002; 22: 440-441.
22. Sciacca P, Romeo MG, Falsaperla R, Mattia C, Betta P. Tornamene G, et al. Transient right ventricular hypertrophy in a newborn infant exposed in utero to nimesulide. Minerva Pediatr 2005; 57: 313-318.
23. Paladini D, Marasini M, Volpe P. Severe ductal constriction in the third-trimester fetus following maternal self-medication with nimesulide. Ultrasound Obstet Gynecol 2005; 25: 357-361.
24. Schiessl B, Schneider KT, Zimmermann A, Kainer F, Friese K, Oberhoffer R. Prenatal constriction of the fetal ductus arteriosus - related to maternal pain medication? Z Geburtshilfe Neonatal 2005; 209:65-68.
25. Gerson A, Abbasi S, Johnson A, Kalchbrenner M, Ashmead G, Bolognese R. Safety and efficacy of long-term tocolysis with indomethacin. Am J Perinatol 1990; 7: 71-74
26. Tarcan A, Gurakan B, Yildrim S, Ozkiraz S, Bilezikci B. Persistent pulmonary hypertension in a premature newborn after 16 hours of antenatal indomethacin exposure. J Perinat Med 2004; 32: 98-99.
27. Saenger JS, Mayer DC, D'Angelo LJ. Ductus-dependent fetal cardiac defects contraindicate indomethacin tocolysis. J Perinatol 1992; 12: 41-47.
28. Gournay V, Roze CJ, Kuster A. Daoud P, Cambonie G, Hascoet JM, et al. Prophylactic ibuprofen vs. placebo in very premature infants: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 1939-1944.
29. Gournay V, Savagner C, Thiriez G, Kuster A, Rozé JC. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet 2002; 359: 1486-1488.
30. Mosca F, Bray M, Stucchi I, Fumagalli M. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet 2002; 360: 1023-10224.
31. Thomas RL, Parker GC, Van Overmeire B, Aranda JV. A meta-analysis of ibuprofen vs. indomethacin for closure of patent ductus arteriosus. Eur J Pediatr 2005;164:135-40
32. Bellini C, Campone F, Serra G. Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus. CMAJ 2006; 174: 143-1844.
33. Kessler RC, McGonagle KA, Zhao S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Study. Arch Gen Psychiatry 1994; 51: 8-19.
34. Thase ME. Treatment of severe depression. J Clin Psychiatry 2000; 61 Suppl 1: 17-25.
35. O'Hara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: prevalence, course and predictive factors. J Abnorm Psycol 1984; 93: 158-171.
36. Reefhuis J, Rasmussen SA. Selective Serotonin-Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn Persistent Pulmonary Hypertension of the Newborn. N Engl J Med 2006; 354: 2188-2189.
37. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones XL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010-1015.
38. Chambers CD, Hernandez-Diaz S, Van Matter LJ, Werler MM, Louik C, Jones KL, et al. Serotonin-Reuptake Inhibitors and persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579-587.
39. Suhara T, Sudo Y, Yoshida K, Okubo Y, Fukuda H, Obata T, et al. Lung as reservoir for antidepressants in pharmacokinetic drug interactions. Lancet 1998; 351: 332-5.
40. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985; 46: 14-9.
41. McMahon TJ, Hood JS, Nossaman BD, Kadowitz PJ. Analysis of responses to serotonin in the pulmonary vascular bed of the cat. J Appl Physiol 1993; 75: 93-102
42. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361:1533-44.
43. Eddahibi S, Raffestin B, Hamon M, Adnot S. Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension? J Lab Clin Med 2002; 139: 194-201
44. Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D, Yaron M. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum 1999; 42: 2561-2568
45. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996; 32:653-658
46. Hallberg P, Odlind V. Selective Serotonin-Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn. N Engl J Med 2006; 354: 2189.
47. Oates M. Suicide: the leading cause of maternal death. Br J Psychiatry 2003; 183: 279-281.
48. Moses-Kolko EL, Roth EK. Antepartum and postpartum depression: healthy mom, healthy baby. J Am Med Womens Assoc 2004; 59: 181-191.
49. Wooltorton E. Persistent Pulmonary Hypertension of the Newborn and maternal use of SSRIs. CMAJ 2006; 174: 1555.
50. Cai RZ, Szoke B, Lu R, Fu D, Redding TW, Schally AV. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci 1986; 83: 1896-1900
51. Mosdell KW, Visconti JA. Emerging indication for octreotide therapy. Part I. Am J Hosp Pharm 1994; 51: 1184-1192
52. Mosdell KW, Visconti JA. Emerging indication for octreotide therapy. Part II. Am J Hosp Pharm 1994; 51: 1317-1330
53. Katz MD, Erstad BL. Octreotide, a new somatostatine analogue. Clin Pharm 1989; 8: 255-273
54. Pawlikowski M, Melen-Mucha G. Perspectives of new potential therapeutic applications of somatostatin analogs. Neuro Endocrinol Lett 2003; 24: 21-27.
55. Vance ML, Laws ER Jr. Role of medical therapy in the management of acromegaly. Neurosurgery 2005; 56: 877-885.
56. Arevalo RP, Bullabh P, Krauss AN. Octreotide-Induced Hypoxemia and Pulmonary Hypertension in Premature Neonates. J Pediatric Surg 2003; 38: 251-253.
57. Silvani P, Camporesi A, Mandelli A, Wolfler A, Salvo I. A case of severe diazoxide toxicity. Pediatric Anesthesia 2004; 14: 607-609.
58. Abu-Osba YK, Manasra KB, Mathew PM. Complications of diazoxide treatment in persistent neonatal hyperinsulinism. Arch Dis Child 1989; 64: 1496-1500.
59. Lindley KJ, Dunne MJ. Contemporary strategies in the diagnosis and management of neonatal hyperinsulinaemic hypoglycaemia. Early Human Develop 2005; 81: 61-72.